EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study

Marta Kaminska, Maja Chrobak, Lucas Sathler Alves Silva, Yasmin Gurtler Pinheiro de Oliveira, Ewa Bielecka, Arthur Dalmaso Pinto, Ruben Horst Duque, Jose Geraldo Mill, Valeria Valim, Piotr Mydel

Rheumatology International · 2026

DOI: 10.1007/s00296-026-06272-4 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Rheumatology International, 2026. Verfasst von Marta Kaminska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Peptidyl-Dipeptidase A, Gingipain Cysteine Endopeptidases, Cardiovascular Diseases. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bergen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed cross-sectional relationships of rheumatoid arthritis (RA) disease activity and cardio-metabolic comorbidities with serum peptidylarginine deiminase 4 (PAD4)-potentiating activity, domain-resolved angiotensin I converting enzyme (ACE1) enzymatic activity, and Porphyromonas gingivalis -specific antibodies. 177 RA patients and 147 healthy controls (HC) were included in the study. Clinical profiling included DAS28, CRP/ESR, treatments, and comorbidities. PAD4-potentiating activity, ACE1 activities, and anti-gingipain antibodies were measured using standardized in-house assays. Associations with RA status, treatments, and outcomes were analysed using covariate-adjusted models; discrimination for selected comorbidities was explored with ROC analyses. PAD4-potentiating activity, anti-Kgp/anti-RgpB and ACE1 activities did not differ between RA and controls. In RA, anti-Kgp showed a weak correlation with DAS28 (Rs=0.17, p=0.033) and was lower with biologic disease-modifying antirheumatic drugs (DMARDs); ACE1 activity was lower among synthetic-DMARDs users across all three substrates (all p≈0.01–0.04). None of the biomarkers showed independent associations with DAS28 in adjusted models. Overall discrimination for cardio-metabolic outcomes was limited; small, predefined strata showed exploratory signals, but low event counts and multiple comparisons constrain inference. In this cohort, between-group differences were limited overall. However, two exploratory within-RA signals emerged: anti-Kgp levels were weakly associated with disease activity and therapy, and lower ACE1 activity was associated with synthetic DMARDs use. Together, anti-Kgp and ACE1 (N-domain) may reflect mucosal-immune and vascular-remodeling axes that could relate to comorbidity patterns and warrant prospective, pre-specified validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPeptidyl-Dipeptidase AGingipain Cysteine EndopeptidasesCardiovascular DiseasesAntibodies, BacterialAutoantibodiesHumansFemaleCross-Sectional StudiesMaleMiddle AgedAgedAdultPorphyromonas gingivalisComorbiditySeverity of Illness IndexProtein-Arginine Deiminase Type 4BiomarkersCase-Control StudiesAntirheumatic Agents

Stichwörter der Autor:innen

Porphyromonas gingivalisAnti-citrullinated protein antibodiesAntibodies, bacterialArthritis, RheumatoidBiomarkersCardiovascular diseasesCross-sectional studiesGingipain cysteine endopeptidasesPeptidyl-Dipeptidase AProtein-arginine deiminase Type 4

Substanzen

Peptidyl-Dipeptidase AGingipain Cysteine EndopeptidasesAntibodies, BacterialProtein-Arginine Deiminase Type 4AutoantibodiesBiomarkersPADI4 protein, humanAntirheumatic Agents

Autor:innen und Institutionen

  • Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
  • Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Department of Rheumatology, University Hospital Cassiano Antônio Moraes - Federal University of Espírito Santo (HUCAM-UFES), Vitória, ES, Brazil.
  • Małopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
  • Department of Physiological Sciences, Health Sciences Center (CCS), Federal University of Espírito Santo (UFES), Vitória, ES, Brazil.
  • Department of Medicine and Postgraduate Program in Public Health (PPGSC), University Hospital Cassiano Antônio Moraes - Federal University of Espírito Santo (HUCAM-UFES), Vitória, ES, Brazil.

Förderung

  • University of Bergen

Zitieren

APA

Kaminska, M., Chrobak, M., Silva, L. S. A., de Oliveira, Y. G. P., Bielecka, E., Pinto, A. D., Duque, R. H., Mill, J. G., Valim, V., & Mydel, P. (2026). Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study. Rheumatology International. https://doi.org/10.1007/s00296-026-06272-4

Vancouver

Kaminska M, Chrobak M, Silva LSA, de Oliveira YGP, Bielecka E, Pinto AD, et al. Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study. Rheumatology International. 2026. doi:10.1007/s00296-026-06272-4

BibTeX
@article{Kaminska2026,
  author = {Kaminska, Marta and Chrobak, Maja and Silva, Lucas Sathler Alves and de Oliveira, Yasmin Gurtler Pinheiro and Bielecka, Ewa and Pinto, Arthur Dalmaso and Duque, Ruben Horst and Mill, Jose Geraldo and Valim, Valeria and Mydel, Piotr},
  title = {Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study},
  journal = {Rheumatology International},
  year = {2026},
  doi = {10.1007/s00296-026-06272-4}
}
Kostenlos starten →